Amylin Pharmaceuticals and Takeda to co-develop obesity treatments

Published: 2-Nov-2009
Research & Development

Amylin Pharmaceuticals in the US and Takeda Pharmaceutical Company of Japan have agreed to co-develop obesity treatments.


Amylin Pharmaceuticals in the US and Takeda Pharmaceutical Company of Japan have agreed to co-develop obesity treatments.

Takeda will pay Amylin an up-front payment of US$75m for products to be developed from Amylin's pipeline, including pramlintide/metreleptin and davalintide, which are currently in Phase II development. Amylin could receive additional payments exceeding US$1bn upon reaching certain milestones, in addition to double-digit royalty payments on global product sales.

Amylin will be responsible for development up to Phase II with the aim of regulatory approval in the US. Takeda will lead development activities beyond Phase II in the US, and all development activities outside the US.

Amylin will have the option to co-commercialise the first two approved products in the US and any follow-on products containing the identical active ingredients.

"Amylin recognises the enormous potential of this collaboration to advance more options in obesity treatment more quickly than either company could do alone," said Daniel Bradbury, chief executive of Amylin Pharmaceuticals.

See more

You may also like

Regulatory

Takeda receives FDA clearance for HyHub devices to simplify HYQVIA administration

Read more
Needle-free infusion tools aim to improve in-home treatment for primary immunodeficiency and CIDP

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  3. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  4. Ryvu to support BioNTech’s clinical trials for cancer in Poland Ryvu will leverage its clinical network to streamline access to BioNTech’s investigational immunotherapies for Polish patients
  5. Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

Takeda receives FDA clearance for HyHub devices to simplify HYQVIA administration

Needle-free infusion tools aim to improve in-home treatment for primary immunodeficiency and CIDP
Research & Development

Nanoform and Takeda team up to advance plasma-derived therapy development

The collaboration will aim to develop plasma-derived therapeutics and accelerate the movement of potential medicines into the clinic
Manufacturing

Takeda's NDA for metastatic colorectal cancer treatment

The FDA has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors
Research & Development

Evox Therapeutics and Takeda sign multitarget rare disease collaboration

Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox’s proprietary exosome technology
Research & Development

Takeda opens new drug research facility in California

The 165,000 sqft facility will play an important role in connecting research collaborators from a local to a global scale
Research & Development

Pharma giants join £9.5 million dementia drug discovery collaboration

Johnson & Johnson Innovation, Takeda and Evotec have joined The Dementia Consortium
Media

Only a handful of pharma companies are developing the urgently needed new medicines for the poor

The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical companies and on five diseases
Subscribe now